

Filed on behalf of Patent Owner Genentech, Inc. by:

David L. Cavanaugh (Reg. No. 36,476)	Adam R. Brausa (Reg. No. 60,287)
Rebecca A. Whitfield (Reg. No. 73,756)	Daralyn J. Durie ( <i>Pro Hac Vice to be filed</i> )
Robert J. Gunther, Jr. ( <i>Pro Hac Vice to be filed</i> )	DURIE TANGRI LLP
Lisa J. Pirozzolo ( <i>Pro Hac Vice to be filed</i> )	217 Leidesdorff Street
Kevin S. Prussia ( <i>Pro Hac Vice to be filed</i> )	San Francisco, CA 94111
Andrew J. Danford ( <i>Pro Hac Vice to be filed</i> )	
WILMER CUTLER PICKERING HALE AND DORR LLP	
1875 Pennsylvania Ave., NW	
Washington, DC 20006	

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.,  
Petitioner,

v.

GENENTECH, INC.,  
Patent Owner.

---

Case IPR2017-02032  
Patent No. 6,407,213

---

**PATENT OWNER'S PRELIMINARY RESPONSE**

**TABLE OF CONTENTS**

	Page
I. INTRODUCTION .....	1
II. BACKGROUND .....	3
A. The Invention of the '213 Patent.....	3
B. Prosecution History .....	4
C. Other IPR Petitions Involving the '213 Patent.....	5
D. The Redundant Boehringer Petitions .....	9
III. ARGUMENT.....	10
A. The Board Should Deny Institution of Grounds 1- 5 Because the Board is Already Considering Those Same Grounds in the Ongoing Celltrion and Pfizer IPRs .....	12
B. The Board Should Deny Institution of Ground 6 Because the PTO Already Determined that the '101 Patent is Not Prior Art. ....	15
C. Inter Partes Review Proceedings Violate the Constitution. ....	17
IV. CONCLUSION.....	18

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Federal Cases</b>	
<i>Cultec, Inc. v. Stormtech LLC</i> , IPR2017-00777, Paper 7 (Aug. 22, 2017) .....	10
<i>Dynamic Drinkware LLC v. Nat'l Graphics, Inc.</i> , 800 F.3d 1375 (Fed. Cir. 2015) .....	2, 16
<i>Google Inc. v. Personal Web Techs., LLC</i> , IPR2014-00980, Paper 10 (Oct. 30, 2014) .....	14
<i>Harmonic Inc. v. Avid Tech., Inc.</i> , 815 F.3d 1356 (Fed. Cir. 2016) .....	10, 16
<i>Hospira, Inc. v. Genentech, Inc.</i> , IPR2017-00739, Paper 16 (July 27, 2017) .....	11, 13, 17
<i>Markman v. Westview Instruments, Inc.</i> , 517 U.S. 370 (1996).....	17
<i>McCormick Harvesting Mach. Co. v. C. Aultman &amp; Co.</i> , 169 U.S. 606 (1898).....	17
<i>Neil Ziegmann, N.P.Z., Inc. v. Stephens</i> , IPR2015-01860, Paper 12 (Feb. 24, 2016).....	17
<i>Neil Ziegmann N.P.Z., Inc. v. Stephens</i> , IPR2015-01860, Paper 13 (Sept. 6, 2017).....	11
<i>R.J. Reynolds Vapor Co. v. Fontem Holdings I B.V.</i> , IPR2017-01118 and IPR2017-01119, Paper 8 (Oct. 4, 2017).....	13
<i>Unified Patents, Inc. v. Berman</i> , IPR2016-01571, Paper 10 (Dec. 14, 2016).....	11
<b>Federal Statutes</b>	
35 U.S.C. § 325(d) .....	<i>passim</i>

**Regulations**

37 C.F.R. § 42.24(d) .....20

37 C.F.R. § 42.122 .....14

**Constitutional Provisions**

U.S. Const. Amendment VII.....17

Genentech, Inc. ("Patent Owner" or "Genentech") submits this Preliminary Response to the Petition that Boehringer Ingelheim Pharmaceuticals, Inc. ("Petitioner" or "Boehringer") filed challenging certain claims of U.S. Patent No. 6,407,213 ("the '213 patent") (Paper 2).

## I. INTRODUCTION

On December 1, 2017, the Board instituted four IPRs in which Celltrion, Inc. (IPR2017-01373 and IPR2017-01374) and Pfizer, Inc. (IPR2017-01488 and IPR2017-01489) have challenged numerous claims of the '213 patent (based on a total of 32 separate grounds). Patent Owner's responses in those proceedings are due on February 15, 2018.

More than three months after Celltrion and Pfizer filed their now-instituted petitions, Boehringer filed the present Petition (and a second petition in IPR2017-02031). The Board should deny institution of the Boehringer petitions for at least two reasons.

*First*, Boehringer copied Grounds 1-5 of this Petition from IPR2017-01373 (Celltrion) and IPR2017-01489 (Pfizer), and copied Grounds 1-3 and 5 of IPR2017-02031 from IPR2017-01374 (Celltrion) and IPR2017-01488 (Pfizer)—without seeking joinder with those earlier-filed proceedings. Boehringer thus asks the Board to institute its IPRs on the *same* grounds *already instituted* in the Celltrion and Pfizer proceedings—but on a schedule trailing those proceedings by

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.